Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 1999

View Archived Issues

Amrad: Annual Report 1998

Corixa is first to achieve clinical testing of a microsphere-encapsulated peptide cancer vaccine

Experiments show skeletal muscle capable of bone formation when transplanted into animals

CytRx reaches midpoint in Flocor trial

Orphan Medical begins Treatment IND trial of Xyrem in narcolepsy

Axcan and Labopharm to develop controlled-release trimebutine formulation

Connetics begins pivotal trial of relaxin for scleroderma therapy

New compounds from Pharmacia & Upjohn interfere in the kynurenine metabolic pathway

New Lilly SERMs especially useful for breast cancer

Ilex Oncology initiates phase III trial of DFMO

ICE/ced-3 cysteine protease inhibitors in development at Idun

FDA grants priority review status to U.S. Bioscience's sNDA for Ethyol

Tachykinin antagonists specifically claimed for asthma by Merck

NNRTIs from Boehringer Ingelheim effective against mutant viruses

Status updated for Esteve's atypical antipsychotic E-5842

Taiwan university researchers present new ATP-sensitive potassium channel opener

AutoImmune and Teva to collaborate on oral immune therapies

Advisory committee votes not to recommend approval of Relenza

Aurora enters assay development and screening agreement with P&U

Strategic review of Novopharm Biotech's R&D program leads to discontinuation of GPI-2A

New tradename announced for Magainin's pexiganan

Celtrix adds another patent to its SomatoKine portfolio

AC-178335: new pure somatostatin antagonist that induces GH release in vivo

Orally active TxA2 antagonist in clinical development at Zeria

MS&D launches alopecia treatment in Spain

Healing of severe esophagitis linked to improvement in peristaltic dysfunction

Preclinical study confirms antiinflammatory activity of raxofelast

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...